Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1988-12-21
|
pubmed:abstractText |
Tumor necrosis factor (TNF), a macrophage secretory protein produced by peripheral blood monocytes from patients with cancer, has been shown to possess cytotoxicity toward tumor cells in vitro. TNF in the blood of individuals with cancer is usually not detectable except with extremely sensitive radioimmunoassay or enzyme-linked immunosorbent assay (ELISA) methods. We have encountered two patients with the rare syndrome of extensive bone marrow necrosis in association with cancer. The first patient presented with marrow failure secondary to necrosis and was found to have adenocarcinoma in thoracic lymph nodes, lung, and marrow lymphatics at autopsy. Plasma tested at two dilutions (1:200 and 1:2,000) contained TNF at a concentration of 8.3 ng/ml, or 80 U/ml by a cytotoxicity assay using LM cells. The presence of TNF was confirmed with immunoblotting. The second patient had a poorly differentiated lymphoid tumor involving bone marrow, pancytopenia, and marrow necrosis. The plasma cytotoxicity assay indicated the presence of 0.7 ng/ml or 7 U/ml TNF. TNF was not detectable in plasma from six other patients with untreated cancer involving bone or bone marrow using either of our methods. The levels of TNF in the two patients with marrow necrosis were greater than those previously measured by others in patients with cancer but were comparable to those noted in patients with lethal sepsis. Since large doses of TNF have been shown to cause organ necrosis in animals, the data presented here are consistent with TNF involvement in mediating the observed marrow necrosis in our patients.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0361-8609
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
215-21
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:3189318-Adenocarcinoma,
pubmed-meshheading:3189318-Adult,
pubmed-meshheading:3189318-Aged,
pubmed-meshheading:3189318-Bone Marrow,
pubmed-meshheading:3189318-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:3189318-Humans,
pubmed-meshheading:3189318-Immunoblotting,
pubmed-meshheading:3189318-Lung Neoplasms,
pubmed-meshheading:3189318-Lymphatic Diseases,
pubmed-meshheading:3189318-Male,
pubmed-meshheading:3189318-Necrosis,
pubmed-meshheading:3189318-Neoplasms, Unknown Primary,
pubmed-meshheading:3189318-Osmolar Concentration,
pubmed-meshheading:3189318-Tumor Necrosis Factor-alpha
|
pubmed:year |
1988
|
pubmed:articleTitle |
Extensive bone marrow necrosis in patients with cancer and tumor necrosis factor activity in plasma.
|
pubmed:affiliation |
Department of Biochemistry, School of Medicine, East Carolina University, Greenville, North Carolina 27858.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Case Reports
|